|
KLF9 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.56730184386333E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.53189699708878E-11 |
| Normal-vs-Stage2 |
2.28309593452991E-11 |
| Normal-vs-Stage3 |
6.26998453157057E-12 |
| Normal-vs-Stage4 |
3.63600261010788E-11 |
| Stage1-vs-Stage2 |
4.364800E-01 |
| Stage1-vs-Stage3 |
2.242800E-01 |
| Stage1-vs-Stage4 |
5.173200E-01 |
| Stage2-vs-Stage3 |
9.082600E-01 |
| Stage2-vs-Stage4 |
9.115600E-01 |
| Stage3-vs-Stage4 |
8.075800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.60379487468276E-11 |
| Normal-vs-AfricanAmerican |
4.66349999950211E-07 |
| Normal-vs-Asian |
1.08901776485482E-12 |
| Caucasian-vs-AfricanAmerican |
1.060210E-01 |
| Caucasian-vs-Asian |
1.261150E-01 |
| AfricanAmerican-vs-Asian |
1.391750E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.45079503965917E-11 |
| Normal-vs-Female |
2.17720286244116E-11 |
| Male-vs-Female |
6.856000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.81930043147349E-11 |
| Normal-vs-Age(41-60Yrs) |
2.40290010111721E-11 |
| Normal-vs-Age(61-80Yrs) |
2.79620770982092E-12 |
| Normal-vs-Age(81-100Yrs) |
2.663000E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.486000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.222210E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.376400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.997580E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.381000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.627400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.763600E-02 |
| Classical-VS-Follicular |
4.347700E-02 |
| Classical-VS-Other |
9.876400E-01 |
| Classical-VS-Normal |
3.00169888944879E-11 |
| Tall-VS-Follicular |
3.942800E-03 |
| Tall-VS-Other |
2.452600E-01 |
| Tall-VS-Normal |
2.32958097257097E-12 |
| Follicular-VS-Other |
5.483200E-01 |
| Follicular-VS-Normal |
2.00149996576471E-09 |
| Other-VS-Normal |
2.95070000000397E-06 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.45180534261158E-11 |
| Normal-vs-N1 |
2.89939960929075E-10 |
| N0-vs-N1 |
8.465600E-01 |
|
|
